Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00754793 · ClinicalTrials.gov registry record · Phase 4
Sinusitis and Facial Pain Disorders Anti-Depression Trial
A Phase 4 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT00754793 is a Phase 4 study that was terminated before completion, run by University of Washington. The registered enrollment target is 3 participants.
The verdict
NCT00754793, a Phase 4 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
The study hypothesis is that the addition of an antidepressant to the standard treatment regimen in patients with both chronic sinusitis and depression or facial pain disorders and depression will decrease the report of chronic sinusitis or facial pain symptom severity. This is a stratified, randomized, double-blind, placebo-controlled study using the drug escitalopram for the treatment of depression in patients experiencing depression and chronic sinusitis or depression and facial pain disorders. It is a 12-week study. Subjects will have a screening visit and then be followed up by phone weekly for four weeks and bi-weekly for 8 weeks.
Interventions
- DRUG placebo
- DRUG escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00754793
The ClinicalTrials.gov registry entry for NCT00754793 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00754793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00754793 about?
NCT00754793 is a clinical study titled "Sinusitis and Facial Pain Disorders Anti-Depression Trial". The study hypothesis is that the addition of an antidepressant to the standard treatment regimen in patients with both chronic sinusitis and depression or facial pain disorders and depression will decrease the report of chronic sinusitis or facial pain symptom severity. This is a stratified, random...
What is the current status of trial NCT00754793?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2009-01. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00754793?
The interventions under investigation include: placebo (DRUG), escitalopram (DRUG).
Who is sponsoring clinical trial NCT00754793?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.